$175 Million

Novavax, Inc.

Bookrunner, December 2022

Senior Convertible Notes Offering

Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax has developed a COVID-19 vaccine (“NVX-CoV2373”), and is developing an influenza vaccine candidate, a COVID-19-Influenza Combination vaccine candidate, and additional vaccine candidates, including for Omicron subvariants, and bivalent formulations with prototype vaccine (NVX-CoV2373). NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization, and emergency use authorization from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

More Like This

Jan 2023
$150 Million

Senior Secured Term Loan

Sole Placement Agent and Exclusive Financial Advisor

View Details >
Dec 2022
Auctus logo

Werksarztzentrum Deutschland GmbH, a Portfolio Company of AUCTUS Capital Partners AG, was Acquired by a PE-Backed Strategic Buyer

Financial Advisor

View Details >
Dec 2022
$86.3 Million
Terns Pharmaceuticals logo

Follow-on Offering


View Details >